The Dutch Colorectal Cancer Group (DCCG) is a collaboration between medical disciplines that are relevant for the diagnosis and treatment of colorectal cancer (surgical oncology radiotherapy medical oncology pathology radiology gastroenterology).

  • English
  • Dutch
Current path: Home » > DCCG trials

CAIRO 2

Introduction

As for the CAIRO study, the accrual of the CAIRO2 study was a great success. In December 2005 the accrual was completed with 755 patients included in 79 Dutch hospitals in less than 2 years. Principal investigator was C.J.A. Punt, translational research was conducted in collaboration with J.H.J.M. van Krieken (UMC St Radboud). The results of an interim safety analysis were presented at ECCO 2007 and published in Annals of Oncology. The final results were presented at ASCO 2008. There were also several side studies connected to the CAIRO2 study, with Jolien Tol (UMC St Radboud) as the primary coordinator and PhD student. Main objective was to search for prognostic and predictive factors on paraffin embedded material for the outcome of treatment. Jan Pander, Hans Gelderblom and Henk-Jan Guchelaar (LUMC Leiden) investigated pharmacogenomics, Mirre de Noo (LUMC Leiden) worked on proteomics, and together with Leon Terstappen and Henk Tissing (Immunicon Enschede) they investigated the predictive and prognostic role of circulating tumour and endothelial cells of which the first results were presented at ASCO GI 2007.

More information

More information about this trial is available at our members only page.

Diagnosis
Meeting

Back to top


Site navigation

Back to top


The Dutch Colorectal Cancer Group (DCCG) is a collaboration between medical disciplines that are relevant for the diagnosis and treatment of colorectal cancer (surgical oncology radiotherapy medical oncology pathology radiology gastroenterology).